Rocket Pharmaceuticals, Inc. Stock price

Equities

RCKT

US77313F1066

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
26.94 USD -1.14% Intraday chart for Rocket Pharmaceuticals, Inc. -2.78% -10.11%
Sales 2024 * 23.11M Sales 2025 * 192M Capitalization 2.44B
Net income 2024 * -262M Net income 2025 * -217M EV / Sales 2024 * 98.1 x
Net cash position 2024 * 172M Net cash position 2025 * 39.19M EV / Sales 2025 * 12.5 x
P/E ratio 2024 *
-10.1 x
P/E ratio 2025 *
-14.3 x
Employees 268
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.49%
More Fundamentals * Assessed data
Dynamic Chart
Rocket Pharmaceuticals Appoints Aaron Ondrey as CFO MT
Rocket Pharmaceuticals, Inc. Announces Appointment of Aaron Ondrey as Chief Financial Officer CI
Rocket Pharmaceuticals, Inc. Announces Executive Appointments CI
UBS Adjusts Rocket Pharmaceuticals Price Target to $54 From $56, Maintains Buy Rating MT
Rocket Pharmaceuticals Q4 Loss Narrows MT
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
North American Morning Briefing : S&P 500 Futures -2- DJ
Rocket Pharmaceuticals Says FDA Extends Review Timeline for Kresladi; Shares Decline MT
FDA Extends Review of Rocket Pharma's Proposed Kresladi DJ
Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi? (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I) CI
Transcript : Rocket Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:45 PM
Certain Common Stock of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023. CI
Certain Warrants of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023. CI
Certain Restricted Stock Units of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023. CI
Certain Stock Options of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023. CI
More news
1 day-1.14%
1 week-2.78%
Current month-8.05%
1 month-7.20%
3 months-12.82%
6 months+29.89%
Current year-10.11%
More quotes
1 week
26.03
Extreme 26.03
27.71
1 month
26.03
Extreme 26.03
31.24
Current year
25.66
Extreme 25.66
31.47
1 year
14.89
Extreme 14.89
32.53
3 years
7.57
Extreme 7.565
49.66
5 years
7.57
Extreme 7.565
67.48
10 years
7.57
Extreme 7.565
67.48
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 18-01-03
President 46 18-01-03
Chief Tech/Sci/R&D Officer 60 15-12-31
Members of the board TitleAgeSince
Director/Board Member 77 18-01-03
Director/Board Member 57 15-12-31
Director/Board Member 63 14-07-31
More insiders
Date Price Change Volume
24-03-28 26.94 -1.14% 498,831
24-03-27 27.25 +2.60% 489,629
24-03-26 26.56 -1.26% 499,223
24-03-25 26.9 -1.14% 310,921
24-03-22 27.21 -1.80% 503,544

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
26.94 USD
Average target price
51.25 USD
Spread / Average Target
+90.24%
Consensus
  1. Stock
  2. Equities
  3. Stock Rocket Pharmaceuticals, Inc. - Nasdaq